دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.07.009
Volume 84, Issue 3, September 2023, Pages e61-e71
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Nick Beije a,b , Wassim Abida c , Emmanuel S. Antonarakis d , Elena Castro e , Ronald de Wit f , Karim Fizazi g , Silke Gillessen h , Maha Hussain i , Joaquin Mateo j , Michael J. Morris c , David Olmos e , Oliver Sartor k , Adam Sharp a,b , Christopher J. Sweeney l , Johann S. de Bono
doi : 10.1016/j.eururo.2023.03.038
Volume 84, Issue 3, September 2023, Pages 253-256
Contemporary Evaluation of Salvage Radiotherapy for Prostate Cancer: Radiotherapy Dose, Field Size, and Use of Hormone Therapy
Tommy Jiang a , Luca F. Valle b,e , Amar U. Kishan
doi : 10.1016/j.eururo.2023.05.012
Volume 84, Issue 3, September 2023, Pages 257-259
A Leak in the System: Addressing the Environmental Impact of Urologic Care
Zachary Kornberg a,y,*, Jaclyn Wu b,y, Helen Wilmot c , Terry Duffina d , Jay B. Shah
doi : 10.1016/j.eururo.2023.04.035
Volume 84, Issue 3, September 2023, Pages 260-262
Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study
Casey Crump a,b,*, Pa¨r Stattin c , James D. Brooks d , Jan Sundquist a,b,e , Anna Bill-Axelson c , Alexis C. Edwards f , Kristina Sundquist a,b,e,y, Weiva Sieh
doi : 10.1016/j.eururo.2023.04.026
Volume 84, Issue 3, September 2023, Pages 263-272
Tackling Depression and Suicide Among Prostate Cancer Survivors: From Clinical Innovations to Continued Advocacy on the Upstream Social Determinants of Health
David-Dan Nguyen a , Raj Satkunasivam b,c,d , Christopher J.D. Wallis
doi : 10.1016/j.eururo.2023.05.042
Volume 84, Issue 3, September 2023, Pages 273-274
Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer
Raquibul Hannan a,b,*, Mark F. McLaughlin a , Laurentiu M. Pop a , Ivan Pedrosa b,c,d , Payal Kapur b,d,e , Aurelie Garant a,b , Chul Ahn b,f , Alana Christie b , James Zhu g , Tao Wang g , Liliana Robles a , Deniz Durakoglugil a , Solomon Woldu b,d , Vitaly Margulis b,d , Jeffrey Gahan b,d , James Brugarolas b,h , Robert Timmerman a,b , Jeffrey Cadeddu
doi : 10.1016/j.eururo.2023.02.016
Volume 84, Issue 3, September 2023, Pages 275-286
Stereotactic Radiotherapy for Renal Cell Carcinoma: The Fallacy of (False) Positive Post-treatment Biopsy?
Rohann J.M. Correa a , Sree Appu b,c , Shankar Siva
doi : 10.1016/j.eururo.2023.03.025
Volume 84, Issue 3, September 2023, Pages 287-288
European Association of Urology Guidelines on Testicular Cancer: 2023 Update
Anna Patrikidou a , Walter Cazzaniga b , Daniel Berney c , Joost Boormans d , Isabel de Angst d , Domenico Di Nardo e , Christian Fankhauser f , Stefanie Fischer g , Carmen Gravina h , Hendrik Gremmels e , Axel Heidenreich i , Florian Janisch j , Ricardo Lea?o k , Nicola Nicolai l , Christoph Oing m , Jan Oldenburg n , Robert Shepherd d , Torgrim Tandstad o , David Nicol b
doi : 10.1016/j.eururo.2023.04.010
Volume 84, Issue 3, September 2023, Pages 289-301
What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel
Fawzy Farag a , Vasileios I. Sakalis b , Serenella Monagas Arteaga c , Ne´ha Sihra d , Markos Karavitakis e , Salvador Arlandis f , Kari B? g , Hanny Cobussen-Boekhorst h , Elisabetta Costantini i , Monica de Heide j , Jan Groen k , Benoit Peyronnet l , Veronique Phe´ m , Mary-Lynne van Poelgeest-Pomfret n , Tine W.L. van den Bos j , Huub van der Vaart o , Christopher K. Harding p,q,y, Marie Carmela Lapitan r,y, Muhammad Imran Omar s,t,y, Arjun K. Nambiar
doi : 10.1016/j.eururo.2023.05.014
Volume 84, Issue 3, September 2023, Pages 302-312
Feasibility and Outcomes of Temporary Bulbar Urethral Stent Placement After Internal Urethrotomy in the Largest Multicenter Series
Omid Sedigh a,b , Ettore Dalmasso c , Andrea Gobbo a,b,*, Mohammad H. Dashti d , Fariborz Bagheri e , Ahmad Shamsodini f , Yaqoub Alqattan a , Farzin Soleimanzadeh g , Nicolo` Maria Buffi b,h , Paolo Gontero i , Jalil Hosseini
doi : 10.1016/j.eururo.2023.05.019
Volume 84, Issue 3, September 2023, Pages 313-320
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
Wassim Abida a,*, David Campbell b , Akash Patnaik c , Alan H. Bryce d , Jeremy Shapiro e , Richard M. Bambury f , Jingsong Zhang g , John M. Burke h , Daniel Castellano i , Albert Font j , Vinod Ganju k , Anne-Claire Hardy-Bessard l , Ray McDermott m , Brieuc Sautois n , Dominique Spaeth o , Eric Voog p , Josep M. Piulats q , Elias Pintus r , Charles J. Ryan s , Axel S. Merseburger t , Gedske Daugaard u , Axel Heidenreich v,w , Karim Fizazi x , Andrea Loehr y , Darrin Despain y , Andrew D. Simmons y , Melanie Dowson z , Jowell Go y , Simon P. Watkins z , Simon Chowdhury
doi : 10.1016/j.eururo.2023.05.021
Volume 84, Issue 3, September 2023, Pages 321-330
Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies
Felix Feng a,*, Branko Miladinovic b , Ke Zhang b , James J. Dignam c , Daniel Wang d , Margaret Yu d , Howard Sandler
doi : 10.1016/j.eururo.2023.05.031
Volume 84, Issue 3, September 2023, Pages 331-340
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)
Thomas W. Flaig a,*, Catherine M. Tangen b , Siamak Daneshmand c , Ajjai Shivaram Alva d , M. Scott Lucia a , David James McConkey e , Dan Theodorescu f , Amir Goldkorn g , Matthew I. Milowsky h , Rick Bangs i , Gary R. MacVicar j , Bruno R. Bastos k,y, Jared S. Fowles l , Daniel L. Gustafson l , Melissa Plets b , Ian M. Thompson Jr. m , Seth P. Lerner
doi : 10.1016/j.eururo.2023.06.014
Volume 84, Issue 3, September 2023, Pages 341-347
Re: WHO Classification of Tumours, 5th Edition, Volume 8: Urinary and Male Genital Tumours
Valentina Tateo a Veronica Mollica a,b Alessandro Rizzo c Matteo Santoni d Francesco Massari
doi : 10.1016/j.eururo.2023.04.030
Volume 84, Issue 3, September 2023, Pages 348-349
Re: A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial
Jennifer R. Majumdar a,b Sigrid V. Carlsson
doi : 10.1016/j.eururo.2023.04.032
Volume 84, Issue 3, September 2023, Pages 349-350
Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Salil S. Ghamande a Zachary Klaassen b,c,* Christopher J.D. Wallis
doi : 10.1016/j.eururo.2023.04.031
Volume 84, Issue 3, September 2023, Pages 350-351
Re: Pulse-Modulated Holmium:YAG Laser vs the Thulium Fiber Laser for Renal and Ureteral Stones: A Single-center Prospective Randomized Clinical Trial
John Denstedt
doi : 10.1016/j.eururo.2023.04.033
Volume 84, Issue 3, September 2023, Pages 351-352
Re: What Is the Prevalence of Hepatic Steatosis on Ultrasonography in Patients Followed for Nephrolithiasis?
Augustin Meria a Paul Meria
doi : 10.1016/j.eururo.2023.05.007
Volume 84, Issue 3, September 2023, Pages 352-353
Re: Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence (NOSTONE)
David C. Chen a,b Aoife McVey a Declan G. Murphy a,c Renu Eapen a,c Nathan Lawrentschuk
doi : 10.1016/j.eururo.2023.05.001
Volume 84, Issue 3, September 2023, Pages 353-354
Is ChatGPT an Evidence-based Doctor?
Zhonghan Zhou a,b,c,d , Xuesheng Wang b,c,d,e , Xunhua Li b,c,d,e , Limin Liao
doi : 10.1016/j.eururo.2023.03.037
Volume 84, Issue 3, September 2023, Pages 355-356
Re: Judikael R. Saout, Gwendoline Lecuyer, Simon Léonard, et al. Single-cell Deconvolution of a Specific Malignant Cell Population as a Poor Prognostic Biomarker in Low-risk Clear Cell Renal Cell Carcinoma Patients. Eur Urol. 2023;83:441–51
Anna Reustle a,b Florian A. Büttner a,b Matthias Schwab a,c,* Elke Schaeffeler
doi : 10.1016/j.eururo.2023.04.036
Volume 84, Issue 3, September 2023, Page e72
Re: Loren K. Mell, Stephanie L. Pugh, Christopher U. Jones, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.01.020
Jaehun Jung a Jae Heon Kim
doi : 10.1016/j.eururo.2023.04.037
Volume 84, Issue 3, September 2023, Pages e73-e74
Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145–51
Jinze Li a,b,1 Bo Chen a,b,1 Dehong Cao
doi : 10.1016/j.eururo.2023.04.040
Volume 84, Issue 3, September 2023, Page e75
Re: Zhonghan Zhou, Xuesheng Wang, Xunhua Li, Limin Liao. Is ChatGPT an Evidence-based Doctor? Eur Urol. 2023;84:355–6.
Lei Peng a,b,y Rui Liang b,c,y Fulin Yi d,y Shaohua Zhang b,* Song Wu
doi : 10.1016/j.eururo.2023.04.042
Volume 84, Issue 3, September 2023, Page e76
Congress Calendar
doi : 10.1016/j.eururo.2023.07.010
Volume 84, Issue 3, September 2023, Pages e77-e79
